Skip to main
HOTH
HOTH logo

Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics (HOTH) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hoth Therapeutics Inc. is advancing its clinical-stage biopharmaceutical portfolio, with promising developments reported for its lead candidate HT-001, which achieved a 100% efficacy rate in reducing skin toxicity and enhancing quality of life in patients during an open-label trial. The company’s strategic initiatives to enhance clinical adoption could strengthen its regulatory positioning and support future submissions based on comprehensive patient data. Additionally, positive interim results from the Phase 2a CLEER-001 trial further underscore HT-001's safety profile and its potential for significant market impact, particularly in oncology and related fields.

Bears say

Hoth Therapeutics Inc. is a clinical-stage biopharmaceutical company that is engaged in developing therapies for various unmet medical needs; however, the company's reliance on multiple developmental assets in early stages presents a significant financial risk due to the potential for prolonged research and development timelines. Furthermore, the lack of revenue generation from approved products raises concerns regarding the company's ability to finance its operations and fund ongoing clinical trials without incurring additional debt or diluting shareholder equity. Additionally, the competitive landscape within the biopharmaceutical sector, coupled with the uncertainties surrounding regulatory approvals and market acceptance of its therapies, contributes to a negative outlook regarding Hoth Therapeutics's stock performance.

Hoth Therapeutics (HOTH) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hoth Therapeutics (HOTH) Forecast

Analysts have given Hoth Therapeutics (HOTH) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Hoth Therapeutics (HOTH) has a Strong Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hoth Therapeutics (HOTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.